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Sessile bacteria growing on surfaces are more resistant to standard antibiotics than their 
planktonic counterpart. Due to their antimicrobial properties, bacteriophages have 
re-emerged as a promising approach to treat bacterial biofilm-associated infections. Here, 
we evaluated the ability of two commercially available phage formulations, Staphylococcal 
bacteriophage (containing the monophage Sb-1) and PYO bacteriophage (a polyphage), 
in preventing and eradicating an in vitro biofilm of methicillin-resistant Staphylococcus 
aureus (MRSA) by isothermal microcalorimetry and high-resolution confocal laser scanning 
microscopy (CLSM). Moreover, to assess the potential in vivo efficacy of both phage 
preparations, a Galleria mellonella model of MRSA systemic infection was used. 
Microcalorimetry measurement showed that 107 PFU/ml (the highest tested titer) of both 
phage formulations were able to inhibit planktonic growth in a concentration-dependent 
manner. However, MRSA biofilm was eradicated only by co-incubation of 5–7 days with 
the highest phage titers, respectively. In the experiments of biofilm prevention, isothermal 
microcalorimetry revealed that the heat production was completely abolished in the 
presence of sub-inhibitory titers (104 PFU/ml) of phages. These data were also confirmed 
by confocal laser scanning microscopy. Both phage formulations increased the survival 
of G. mellonella larvae preventing or treating MRSA infection compared to untreated 
control. In conclusion, tested phage formulations are promising for preventing device 
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INTRODUCTION
Staphylococcus aureus is causing a variety of community-
acquired and healthcare-associated infections (Magill et  al., 
2014; Tong et  al., 2015). In addition, S. aureus exhibits the 
ability to form biofilm on either native tissues or implanted 
medical devices resulting in tolerance to high concentrations 
of antimicrobials (Zimmerli et al., 2004; Arciola et al., 2012). 
Infections caused by biofilm-embedded bacteria are difficult 
to eradicate due to an extracellular polymeric matrix, which 
protects them from antimicrobials and host immune cells 
(de la Fuente-Nunez et al., 2013; Paharik and Horswill, 2016). 
Indeed, the heterogeneity of the biofilm cell populations, 
including antibiotic-tolerant persister cells, characterized by 
a slow- or non-growing state, makes biofilm-embedded bacteria 
significantly less susceptible to antimicrobials than their free-
floating counterparts (Van Acker et  al., 2014; Flemming 
et  al., 2016). Moreover, the emergence of spreading of 
staphylococcal strains resistant to different antimicrobial 
agents, including methicillin, vancomycin, daptomycin and/
or rifampicin (O’Neill et  al., 2006; Kos et  al., 2012; Hassoun 
et  al., 2017; Ma et  al., 2018) represents a serious threat to 
global health (Sugden et  al., 2016; Monaco et  al., 2017).
This scenario is further complicated by the fact that production 
pipelines for the development of novel antibiotics has been 
running dry over the past few decades, resulting in an crucial 
requirement to identify novel therapeutic strategies to control 
bacterial infections mainly due to multi-drug resistant bacteria 
embedded in a biofilm (Ribeiro et  al., 2016).
Bacteriophage (phage) therapy, based on the employment 
of viruses specifically killing bacterial cells, is considered an 
encouraging option for treating staphylococcal infections which 
result refractory to conventional antibiotics (Gordillo Altamirano 
and Barr, 2019). After the discovery of bacteriophages by 
d’Herelle in 1917, phages as therapeutic agents have been 
used for almost century mainly in the Eastern European 
countries in humans (Kutateladze and Adamia, 2010). However, 
with the launching of conventional antibiotics, the application 
of phage therapy in Western countries promptly decreased 
(Kortright et  al., 2019). The rapid increase of multi-drug-
resistant bacterial strains recently has been renewed interest 
in phage therapy and even though regulatory authorities in 
Europe and U.S. have not approved it yet, several examples 
of successfully applications of personalized phage therapy have 
been reported (Jennes et al., 2017; Chan et al., 2018; Exarchos 
et  al., 2019; Nir-Paz et  al., 2019; Tkhilaishvili et  al., 2019) 
as compassionate use under the umbrella of Article 37 of 
the Helsinki Declaration.
Phage therapy offers some advantages over conventional 
antimicrobial strategies. Due to their high specificity, 
bacteriophages attack only host bacterial cells without affecting 
the normal microflora (Ly-Chatain, 2014). Unlike antibiotics, 
bacteriophages are self-propagating and self-limiting viruses, 
regulating themselves at the site of infection. This behavior 
results in a localized increase in viral particle numbers with 
a low initial dose as long as the targeted bacteria are present 
and in a decrease when bacteria have been killed (Dabrowska, 
2019). Moreover, since the resistance mechanisms arose for 
all class of antibiotics do not alter phage infection, phages 
have been demonstrated to kill multidrug-resistant bacterial cells.
In addition, for different phages, the ability to reduce in 
vitro viable sessile bacterial cells was also proved (Khalifa et al., 
2015; Liu et  al., 2016; Kumaran et  al., 2018), suggesting a 
potential use for the treatment of biofilm-associated infections.
Among commercially available phage formulations for 
therapeutic use in human, Staphylococcal bacteriophage (Sb) and 
PYO bacteriophage (PYO) were developed and employed as anti-
infective treatments at Eliava Institute in Georgia (Fish et  al., 
2018; Ujmajuridze et  al., 2018). Sb is a mono phage preparation 
that contains a well characterized and fully sequenced virus Sb-1 
(Kvachadze et  al., 2011), whereas PYO is a complex preparation 
targeting different bacterial species including S. aureus, Streptococcus 
spp., E. coli, Pseudomonas aeruginosa, and Proteus spp. with batch 
to batch variations (Kvachadze et al., 2011; Villarroel et al., 2017).
Sb has been successfully employed to treat S. aureus infections 
in different patients suffering from digital osteomyelitis and 
foot ulcers (Fish et  al., 2016). Analogously, PYO have been 
used to cure staphylococcal wound infections by either washing 
the wound or applying a dressing impregnated with the phage 
cocktail (Pokrovskaya et  al., 1942; Markoishvili et  al., 2002).
Recently, we  have showed that Sb is able to degrade the 
components of extracellular matrix and be  effective against 
persister cells of S. aureus (Tkhilaishvili et al., 2018b). In addition, 
this phage formulation exhibited a rapid synergistic activity in 
eradicating S. aureus biofilm after 24 h-treatment in combination 
with different classes of antibiotics (Tkhilaishvili et  al., 2018b).
Although both phage formulations were widely used in 
Former Soviet Union (Sulakvelidze et  al., 2001; Myelnikov, 
2018), their lytic effect against sessile bacteria has not been 
investigated in a preclinical setting yet.
Here, we  evaluated the ability of Sb and PYO to prevent 
and eradicate an in vitro biofilm of methicillin-resistant S. 
aureus (MRSA) by isothermal microcalorimetry (IMC) and 
high-resolution microscopy. In addition, the in vivo efficacy 
of both phage formulations was also evaluated in a Galleria 
mellonella model of S. aureus systemic infection.
colonization and killing biofilm bacteria attached on a surface. Novel strategies for direct 
coating and release of phages from material should be investigated.
Keywords: methicillin-resistant Staphylococcus aureus, biofilm-associated infection, antimicrobial activity, 
bacteriophages, Galleria mellonella, phage therapy, isothermal microcalorimetry, confocal laser scanning 
microscopy
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MATERIALS AND METHODS
Bacterial Strains and Bacteriophages
MRSA ATCC 43300 was used for all experiments. Bacteria were 
stored in a cryovial bead preservation system (Roth, Karlsruhe, 
Germany) at −80°C. Bacterial strains were grown on blood 
agar plate (VWR Chemicals, Leuven, Belgium) at 37°C for 24 h. 
Inoculum was prepared according to a McFarland (BioMerieux 
Marcy l’Etoile, France) turbidity of 0.5 (≈1–5  ×  108  CFU/ml 
of the tested strain). Commercially available formulations of 
staphylococcal bacteriophage and PYO bacteriophage were 
obtained as 10 ml liquid ampoules from the Eliava Biopreparations, 
a company associated with the G. Eliava Institute of Bacteriophages, 
Microbiology and Virology, Tbilisi, Georgia. PYO formulation 
Phage stocks were maintained at 4°C. Vancomycin was supplied 
by Teva Pharma AG (Aesch, Switzerland) as 10  mg of powder 
in ampoules. The stock solution of 50  mg/ml was prepared in 
sterile saline.
Titration of Bacteriophage Suspensions
Phages titers were determined by a quantitative plaque assay 
as previously described (Tkhilaishvili et  al., 2018a). Phage 
formulations were diluted using 10-fold serial dilutions in 
phosphate buffer to an estimated concentration yielding plaque 
numbers that could easily be counted. From appropriate dilutions, 
0.5  ml bacteriophage lysate and 0.3  ml host bacteria from 
overnight culture were added to 3  ml top agar (ca. 50°C) and 
immediately poured onto Brain-Heart Infusion agar plates. Two 
plates for each dilution were used. After overnight incubation 
of plates at 37°C, plaques were counted and the titer was 
calculated in PFU/ml.
Microcalorimetry Assay
An isothermal calorimetry instrument (Thermal Activity Monitor, 
Model 3,102 TAM III, TA Instruments, New Castle, DE, USA) 
equipped with 48 channels was used to determine the 
antimicrobial activity of bacteriophages, as previously reported 
(Tkhilaishvili et  al., 2018a,b). Airtight sealed ampoules were 
sequentially introduced into the microcalorimetry channels and 
lowered to an equilibrium position for 15  min to reach a 
temperature of 37°C. The heat generated in real-time by 
planktonic and biofilm-embedded cells treated with phages and 
by recovering bacteria after treatment were continuously 
measured. Heat flow (μW) was measured at 120  s-intervals 
and recorded for either 24 or 48  h.
Phage Lytic Activity Against Planktonic 
Methicillin-Resistant Staphylococcus 
aureus by Isothermal Microcalorimetry 
and CFU Counting
Free-floating bacteria were added to microcalorimetric ampoules 
containing 3  ml of BHIB (final inoculum 1–5   ×   106  CFU/ml) 
and 10-fold serial dilutions of phages (ranging from 102 to 107 
PFU/ml). A growth control containing bacteria without phages, 
as well as a negative control with phages only was also included. 
Bacterial heat production was monitored for 24  h at 37°C and 
data were plotted as heat flow (in μW) and total heat (J) versus 
time. The minimum heat inhibiting concentration of phages 
(MHICP) was defined as the lowest titer inoculated with bacteria 
at the experiment starting point that inhibited growth-related 
heat production during 24 h-incubation in the microcalorimeter 
by more than 90% in comparison to the untreated control 
(growth control). After calorimetric analysis, 50 μl of the culture 
and related 10-fold serial dilutions were plated onto BHI agar 
for colony counting. MBC was defined as the minimum 
bactericidal titer of phages which determined a reduction of 
more than 3 log10 CFU/ml comparing to the CFU/ml of inoculum 
size. Experiments were performed in triplicate.
Phage Lytic Activity Against Biofilm 
Methicillin-Resistant Staphylococcus 
aureus by Isothermal Microcalorimetry 
Testing and Sonication/Colony Counting
Real-Time Isothermal Microcalorimetry
MRSA biofilms were formed on porous glass beads having a 
diameter 4 mm, pore size 60 μm, and surface area approximately 
60  cm2 (VitraPor; ROBU, Hattert, Germany). Briefly, 10 beads 
were statically incubated with 2–3 colonies of MRSA into 10 ml 
BHI broth at 37°C. After 24 h incubation, beads were carefully 
washed three times using sterile PBS and incubated with 10-fold 
serial dilution phage titers (ranging from 102 to 107 PFU/ml) 
into the microcalorimetry glass ampoules filled with a final 
volume of 3  ml fresh BHI broth. Sterile beads and beads with 
untreated biofilm were also included as a negative (sterility) 
and positive (growth) control. IMC analyses were recorded 
for 48  h at 37°C. The minimal heat inhibitory concentration 
of phages for biofilm (MHICPbiofilm) bacteria was defined as 
“the lowest phage titer inhibiting growth-related heat production 
related to the viability of biofilm cells during 48  h-incubation 
in the microcalorimeter more than 90% (corresponding more 
than 2 log10-reduction of CFU) compared to the growth control. 
Experiments were performed in triplicate.”
Evaluation of the Eradication of Biofilm 
Methicillin-Resistant Staphylococcus aureus  
by Isothermal Microcalorimetry
Twenty-four-hour-old biofilms on the beads prepared as described 
above were co-incubated to the 10-fold serial dilution 
bacteriophage titers (ranging from 102 to 107 PFU/ml) in plastic 
FAC tubes (Corning Science, Reynosa, Mexico) for 24–48–72–
120–168 h. Then, beads were carefully rinsed (3×) using sterile 
PBS to remove planktonic bacteria and phages, incubated in 
ampoules with fresh medium and inserted into the calorimeter 
for the eradication analysis. Growth medium with untreated 
beads was used as the positive (growth) control, and growth 
medium with sterile beads served as the negative (sterility) 
control. The minimum biofilm bactericidal concentration of 
phages (MBBCP) was defined as the lowest antimicrobial 
concentration that strongly reduced the number of viable 
bacterial cells within the biofilm, and therefore leading to 
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undetectable heat values for 24–48  h. Experiments were 
performed in triplicates.
Biofilm Prevention Assay by  
Isothermal Microcalorimetry
An inoculum, prepared according to a McFarland standard 
turbidity of 0.5 was diluted to a final concentration of 1–5 × 106 
CFUs/ml, as reported above. Ten beads were incubated with 
1–5   ×   106  CFU/ml of MRSA together with 10-fold serial 
dilution phage titers (ranging from 102 to 107 PFU/ml) into 
10  ml BHI broth for 24  h at 37°C in static condition. After 
24  h-incubation, beads were carefully rinsed (3×) with sterile 
PBS and incubated in sterile glass ampoules with 3  ml BHI 
broth. Sterile beads and beads with untreated biofilm were 
also here included as a negative (sterility) and positive (growth) 
control. The IMC analysis was performed at 37°C for 48  h, 
defining the minimum biofilm preventing concentration (MBPCP) 
of phages as the lowest phage titer that prevented the formation 
of biofilm on the glass beads, thus leading to an undetectable 
heat flow signal during 48  h-incubation in the calorimetry.
Sonication/Colony Counting
After IMC biofilm experiments, to evaluate the reduction/
eradication of biofilm cells, the beads showing no heat production 
together with untreated biofilms (growth controls) were washed 
(3×) using sterile PBS to remove the rest of phages and planktonic 
bacteria and transferred to individual Eppendorf tubes with 
1  ml saline. Beads were vortexed for 30  s with maximum 
power, sonicated at 40  kHz for 60  s in a sonication bath 
(BactoSonic; Bandelin Electronic, Germany), and vortexed for 
30 s again to dislodge biofilm bacteria. For conventional culture, 
sonication fluids were serially diluted in Eppendorf tubes and 
aliquots of 50  μl were quantified by viable count of CFU/ml. 
In unpublished control experiments, in which S. aureus cultures 
were sonicated up to 30  min (with the same above mentioned 
conditions), no statistically significant difference in CFU values 
was observed in comparison to non-sonicated cultures, indicating 
that under these conditions sonication does not kill bacteria. 
The minimum biofilm eradicating concentration (MBECP) of 
phage titers was defined as MBBCP titers, but resulting in 
0 CFU/ml on plates after CFU counting of the sonicated beads, 
as previously described (Tkhilaishvili et  al., 2018b).
Confocal Laser Scanning Microscopy
The lytic effect of phage on the prevention of biofilm formation 
and its eradication was evaluated by CLSM. Brieflyan overnight 
bacterial culture (diluted 1:100) was distributed into an 8-well 
μ-Slide (Ibidi) to form biofilm. For prevention experiments, 
bacteria were simultaneously incubated (at 37°C for 24  h) in 
the presence of different titres of phages. For eradication 
experiments, bacteria were first let form biofilm into an 8-well 
μ-Slide (Ibidi) for 24 h at 37°C, and then treated with different 
phage titers. Bacteria viability and biofilm thickness after phage 
co-incubation/treatment was determined by CLSM after staining 
cells with Syto9 (488  nm/500–540  nm) and propidium iodide 
(PI) (561 nm/600–650 nm) as recommended by the manufacturer 
(Live/dead BacLight Bacterial Viability Kit Molecular Probes, 
Life technologies). Samples were analyzed by the microscope 
TCS SP5 (Leica, Heidelberg, Germany) using a 63× objective 
and a pinhole aperture of 1.0 Airy. For each image, the mean 
of fluorescent intensity was calculated as previously described.
Phage Treatment in a Galleria mellonella 
Model of Methicillin-Resistant 
Staphylococcus aureus Infection
Larvae of G. mellonella were obtained from BioSystems Technology 
Ltd. (Exeter, Devon, UK). Larvae were stored at room temperature 
and were used within 3 days. Phages were tested for their ability 
to rescue MRSA-infected larvae from death. Bacteria were prepared 
for injection as previously described (Gibreel and Upton, 2013). 
Larvae were inoculated with 10  μl of bacterial suspension 
(containing ≈ 2.5–5  ×   106–2.5–5    ×   107  CFU) in the last left 
proleg. For the treatment, phages (1   ×   105 PFU) or vancomycin 
(10 mg/kg) were delivered behind the last proleg on the opposite 
side to the bacterial injection site either 1  h post-infection (for 
treatment experiments) or 1  h pre-infection (for prevention 
experiments). Ten larvae per treatments were issued in all 
experiments. Larvae infected and treated with PBS solution served 
as positive control group. Three negative control groups were 
also included in the experimental design: one group that underwent 
no manipulation, one group injected with PBS only, which 
controlled for the impact of any negative effect from the injection 
process, and one group injected with phage suspension only, 
assessing phage toxicity. Larvae were stored in Petri dishes in 
the dark at 37°C for 168  h. Larvae were inspected every 24  h 
and were considered dead if they did not move when stimulated.
Data Analysis
Microcalorimetry data analysis was accomplished using the 
manufacturer’s software (TAM Assistant; TA Instruments, New 
Castle, DE). Figures were plotted using GraphPad Prism 6.01 
(GraphPad Software, La Jolla, CA, USA), and resulted data 
were expressed as heat flow (μW) and total heat (J) versus 
time (h). In the G. mellonella model of infection, survival 
data were plotted using the Kaplan-Meier method.
RESULTS
Antibacterial Activity of Sb and PYO  
versus Planktonic Methicillin-Resistant 
Staphylococcus aureus
The viability of planktonic MRSA was investigated in real-time 
over 24  h by IMC measuring the heat produced by MRSA in 
the presence of phages and by CFUs counting after phage 
treatment (Figure  1). An untreated growth control was also 
added. As shown in Figures  1A,C, either Sb or PYO rapidly 
inhibited the planktonic growth of MRSA in a titer-dependent 
manner compared to the untreated growth control. Indeed, no 
heat production was observed in the presence of 107 PFU/ml 
of both phage formulations within 24  h-incubation, indicating 
that 107 PFU/ml titer corresponds to MHICP.
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A similar dose-dependent trend was observed by colony 
counting of bacteria after 24  h incubation with different phage 
titers. As shown in Figures  1B,D, an increase of ≈2 log10 CFU/
ml was observed in the GC samples, as compared to the inoculum 
size (T0). A reduction of more than 2 log10 was already obtained 
with 104 PFU/ml of Sb and PYO phages, respectively, compared 
to the CFU/ml number of MRSA initial inoculum (1–5 × 
106  CFU/ml). In the presence of 107 PFU/ml titers of both 
phage formulations, no CFUs were observed (plating detection 
limit  =  20  CFU/ml), suggesting that such titer is MBCP.
Antibacterial Activity of Sb and PYO 
Against Biofilm-Embedded Methicillin-
Resistant Staphylococcus aureus
The interaction between phages and 24 h-old S. aureus biofilm 
was also analyzed in real-time by microcalorimetric measurements. 
The thermogenic curves of biofilm-embedded cells treated and 
untreated with phages are shown in Figure  2. Either Sb and 
PYO inhibited the replication of sessile bacteria in a titer-
dependent manner compared to the growth control, resulting 
in a suppression of the heat production over 48  h-incubation 
(Figures  2A,C). However, a reduction of more than 90% of 
the total heat produced by MRSA biofilm-embedded cells was 
observed at 107 PFU/ml titers for both phage formulations 
and therefore was defined as MHICPbiofilm.
Then, the evaluation of viable bacteria attached to the beads 
was performed by colony counting after bead sonication and 
plating of the sonication fluids. A similar dose-dependent trend 
of reduction of MRSA CFUs/ml was observed for all samples 
treated with both phages, as compared to the untreated growth 
control (Figures  2B,D). Here, the colony counting showed a 
reduction of more than 2 log10 when bacteria were treated 
with 107 PFU/ml of Sb and more than 3 log10 with 107 PFU/
ml of PYO phage compared to the growth control (plating 
detection limit  =  20 CFUs/ml). The lack of an eradication at 
higher titers after 24  h of phage treatment was also confirmed 
by CLSM (Figure  3).
In our previous work, we  have shown that Sb is able to 
degrade the extracellular polysaccharide matrix of S. aureus 
biofilm (Tkhilaishvili et  al., 2018b). By using CLSM, we  also 
assessed the effect of PYO on extracellular matrix (Figure  4). 
Twenty-four-hour-old biofilm of MRSA was stained with both 
a dye specific for the poly-N-acetylglucosamine residues (blue) 
of the extracellular polysaccharides and with syto 85 specific 
for the cellular DNA (green). In contrast to what observed 
for Sb (Tkhilaishvili et al., 2018b), none of PYO titers determined 
a progressive reduction of the blue staining in comparison to 
A B
DC
FIGURE 1 | Evaluation of MRSA ATCC43300 susceptibility to Sb (A,B) and PYO (C,D) exposure, by isothermal microcalorimetry (A,C) and colony counting (B,D). 
Each curve shows the effect of different titers of phages on the heat produced by viable bacteria during 24 h of treatment with Sb (A) and PYO (C). Histogram 
represents the mean of CFU number ± SEM of planktonic MRSA treated/untreated with Sb (B) and PYO (D). Numbers above curves represent Sb titers (PFU/ml). 
GC, growth control (dashed line); NC, negative control; T0, initial inoculum.
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the untreated control, suggesting that no visible degradation 
of the polysaccharide component seems to occur in the presence 
of PYO phages.
Moreover, isothermal microcalorimetry was used to investigate 
the presence of residual biofilm cells attached on glass beads 
in terms of metabolic heat production. Beads were re-inoculated 
in fresh medium, after incubation with different phage titers 
and at different time points (ranging from 24  h up to 168  h). 
Indeed, co-incubation with increasing titers of either Sb and 
PYO formulations over the time led to a minor heat production 
compared to the heat released by untreated controls, suggesting 
a strong decrease in the number of alive bacteria attached on 
the beads when treated with phages (Figures 5, 6, respectively).
The analysis of sonication fluids of bead biofilms pre-treated 
with phages and incubated in the calorimeter at 37°C for 24  h 
in fresh medium revealed that MRSA biofilm was eradicated 
only following a co-incubation with the highest titer of Sb and 
PYO, for either 7 or 5  days, respectively (Figures  5E, 6D). 
A B
DC
FIGURE 2 | Evaluation of MRSA ATCC43300 biofilm susceptibility to either Sb (A,B) or PYO (C,D) exposure, by isothermal microcalorimetry (A,C) and colony 
counting (B,D). Each curve shows the heat produced by viable bacteria attached on beads during 48 h treatment with different titers (ranging from 102 to  
107 PFU/ml) of Sb (A) and PYO (C), respectively. Histogram represents the mean of CFU number ± SEM of biofilm dislodged MRSA treated/untreated with Sb (B) 
and PYO (D). Numbers above curves represent Sb titers (in PFU/ml). GC, growth control (dashed line); NC, negative control.
FIGURE 3 | CLSM images of MRSA ATCC 43300 biofilm treated with/without phages. MRSA biofilm (24 h-old) was exposed for further 24 h to different phage titers 
(104–107 PFU/ml). The viability of the cells was evaluated staining biofilm with SYTO9 (488/500–540 nm – green) for alive bacteria and with propidium iodide (PI) 
(561/600–650 nm – red) for dead bacteria. Images are merged from the two channels. Upper and lower panels represent xy- and z-plans, respectively. Scale bar: 25 μm.
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These results were confirmed by CLSM imaging of MRSA 
biofilm treated for 7 and 5  days with Sb and PYO, respectively. 
The analysis of MRSA viability by dead/live staining clearly 
indicating that no biofilms were detectable after the treatment 
of MRSA biofilm with phages (Figure  7). By definition, 107 
PFU/ml and 106 PFU/ml were the MBEC of Sb and PYO after 
7 and 5  days, respectively.
Ability of Sb and PYO to Prevent 
Methicillin-Resistant Staphylococcus 
aureus Biofilm Formation
Microcalorimetric measurements were also performed to evaluate 
the ability of bacteriophages in preventing biofilm formation 
on glass beads. In this experiment, by using microcalorimetry, 
we  aimed at evaluating if any biofilm or attached bacteria were 
present on the beads which were previously co-incubated with 
phages and bacteria (simultaneously), for 24 h. After co-incubation, 
beads were washed to remove free floating phages and bacteria 
and then inoculated in fresh medium in the calorimeter. If 
phages prevented bacterial attachment and biofilm formation, 
beads had no bacteria on top, so no heat was produced within 
48  h of measuring. Figure  8 shows the heat flow detected 
during 48  h monitoring of heat produced by MRSA, generated 
by viable bacteria attached on the beads, previously co-incubated 
with either Sb (Figure  8A) or PYO phage (Figure  8B).
A strong reduction of MRSA heat production was already 
achieved at a lower titer (102 PFU/ml) of both bacteriophages, 
and a reduction of more than 90% of heat production was 
already observed at 104 PFU/ml of both phage formulations. 
FIGURE 4 | CLSM images of MRSA ATCC 43300 biofilm treated with/without PYO. MRSA biofilm (24 h old) was exposed for 24 h to different PYO titers (ranging 
from 0 to 106 PFU/ml) and then stained with WGA488 (488/500–600 nm – blue) for exopolysaccharides and SYTO™85 (561/600–700 nm – green) for bacterial 
cells. Scale bar: 25 μm.
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FIGURE 5 | Evaluation of MRSA ATCC43300 biofilm susceptibility to Sb phage at different time exposures by IMC. Each curve shows the heat produced by viable 
bacteria present in the biofilm after 24 h (A), 48 h (B), 72 h (C), 120 h (D), 168 h (E), treatment with different phage titers (ranging from 102 to 107 PFU/ml). Graphs 
on the right represent the magnification of the graphs on the left. Numbers above curves represent Sb titers (in PFU/ml). Circled values represent the MBEC. GC, 
growth control (dashed line); NC, negative control.
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FIGURE 6 | Evaluation of MRSA ATCC43300 biofilm susceptibility to PYO at different time exposures by IMC. Each curve shows the heat produced by viable 
bacteria present in the biofilm after 24 h (A), 48 h (B), 72 h (C), 120 h (D), 168 h (E) treatment with different phage titers (ranging from 102 to 107 PFU/ml). Graphs 
on the right represent the magnification of the graphs on the left. Numbers above curves represent PYO titers (in PFU/ml). Circled values represent the MBECP. GC, 
growth control (dashed line); NC, negative control.
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The lack of heat production for 48 h correlated with no biofilm-
embedded cells attached on porous surface of glass beads.
These results were confirmed by CLSM analysis of the 
presence of biofilm MRSA, whose planktonic cells were previously 
incubated with phages and then labeled by dead/live staining. 
As shown in Figure  9, a strong reduction or the absence of 
the alive bacterial cells attached on the wilco surface after 
co-incubation with 103 PFU/ml and 104 PFU/ml, of both phages 
compared to the untreated control was observed.
In order to better understand the absence of heat production 
detected by microcalorimetric experiments, the evaluation of 
viable bacteria attached on the beads or free-swimming bacteria 
in the supernatant was performed by colony counting of either 
sonication fluids or supernatants. As shown in Figure  10, 
sub-inhibitory titers (104 PFU/ml) of both phages formulations 
within 6  h of co-incubation showed a reduction of more than 
3 log10 of free-floating bacteria in the liquid medium, besides 
≈102  CFU/ml of bacteria was attached on the beads. However, 
after 24  h of co-incubation within phages, no colonies were 
detected, neither in the liquid medium nor in the sonication 
fluid. A dose-dependent correlation was observed during colony 
counting of bacteria with increasing the titer of phages.
Prophylaxis and Treatment of Methicillin-
Resistant Staphylococcus aureus 
Systemic Infection in Galleria mellonella 
Larvae by Either Sb or PYO Phages
To evaluate the application of the phages as prophylactic or 
remedial treatment for MRSA infection, we  determined their 
FIGURE 7 | CLSM images of MRSA ATCC 43300 biofilm untreated and treated with Sb and PYO. MRSA biofilm (24 h-old) was exposed for 7 and 5 days to 107 
PFU/ml Sb and 106 PFU/ml PYO, respectively. The viability of the cells was evaluated staining with green fluorescent labeled SYTO9 (488/500–540 nm) for alive 
bacteria and with red fluorescent propidium iodide (PI) (561/600–650 nm) for dead bacteria. Images are merged from the two channels. Upper and lower panels 
represent xy- and z-plans, respectively. Scale bar: 25 μm.
A B
FIGURE 8 | Evaluation of the ability of Sb (A) and PYO (B) phages to prevent biofilm formation on porous glass beads by IMC. Each curve shows the heat 
produced by viable bacteria potentially attached on the glass beads after 24 h co-incubation with increasing titers of phages (ranging from 102 to 107 PFU/ml) in the 
presence of the abiotic surface. Numbers above curves represent Sb titers (in PFU/ml). GC, growth control (dashed line); NC, negative control.
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efficacy in the G. mellonella larvae using the same bacterial 
strain and phages combination used for the in vitro assays 
(Figures 11, 12). Two models of phage therapy were examined. 
The first was a treatment whereby an acute 1  h infection was 
allowed to establish prior to administration of phage or 
vancomycin (Figure 11); in the second model, a phage formulation 
or vancomycin was administered to larvae 1 h prior to bacterial 
challenge to prevent infection (Figure 12). No mortality was 
recorded in the negative controls. Moreover, phages (105 PFU/
ml) and vancomycin 10  mg/kg alone had no effect on larval 
survival, as compared to the PBS-treated controls and were 
therefore considered to be non-toxic at these doses. Larval 
survival was affected by the inoculum dose, with higher doses 
of bacteria (2.5 × 107 CFU/ml) reducing the time of larval survival 
(Figures  11B, 12B). Single treatment with different doses of 
phages or antibiotic administered before or after inoculation 
with MRSA improved larval survival. However, the groups with 
a lower inoculum (2.5 × 106  CFU/ml) had a greater survival 
FIGURE 9 | CLSM analysis of biofilm of MRSA ATCC 43300 preventively incubated with either Sb or PYO. The viability of the cells attached on the surface was 
evaluated after 24 h incubation staining with green fluorescent labeled SYTO9 (488/500–540 nm) for alive bacteria and with red fluorescent propidium iodide (PI) 





FIGURE 10 |  The evaluation of viable bacteria attached on the beads (B,D) or free-swimming bacteria (A,C) in the supernatant. Histogram represents the mean of 
CFU number ± SEM of biofilm MRSA treated/untreated with different titer of Sb (A,B) and PYO (C,D) phages (ranging from 104–107 PFU/ml). GC, growth control.
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percentage (Figures 11A, 12A). In addition, the results showed 
that increased survival rate was observed with the usage of a 
phage cocktail, as compared to single phage administration.
DISCUSSION
The emergence of antibiotic resistance has reduced the available 
treatment options for bacterial infections (O’Connell et  al., 
2013; Li and Webster, 2018). Moreover, the ability of S. aureus 
to form biofilm in the presence of a medical indwelling device 
represents an additional challenge, since only few antibiotics, 
such as vancomycin, daptomycin, fosfomycin, and rifampicin, 
result effective for the treatment of staphylococcal biofilm-
associated infections (Singh et  al., 2010; Mihailescu et  al., 
2014). In most cases, biofilm bacteria are tolerant to high 
concentrations of antibiotics due to the presence of persisters, 
a subpopulation of bacterial cells phenotypically tolerant to 
antibiotics, determined the need of prolonged therapies (Lebeaux 
et  al., 2014; Butini et  al., 2019). As a result, bacteriophages 
have been re-emerged as potential alternative strategy for the 
treatment of biofilm-associated infections (Wu et  al., 2015; 
Pires et  al., 2017).
Among different commercially available phage formulation, 
Sb is constituted of Sb-1 a fully sequenced single phage 
preparation, while PYO is a cocktail of different phages and 
the one used in this study contained the completely sequenced 
Staphylococcal phage ISP (Vandersteegen et  al., 2011).
In our previous work, by using IMC, we  observed that 
T3 phage exerted killing activity against planktonic and 
biofilm-embedded E. coli in a titer dependent manner and 
the highest titer tested (107 PFU/ml) was able to kill all 
planktonic cells, but it was not able to eradicate sessile 
bacteria after 24  h incubation (Tkhilaishvili et  al., 2018a). 
A similar trend was observed here. Microcalorimetric analysis 
in real-time showed that the incubation with 107 PFU/ml 
titer of either Sb or PYO exhibited a killing activity versus 
sessile cells of S. aureus ATCC43300, but it did not result 
in an eradication of the biofilm within 24  h, as attested 
even by colony counting and CLSM imaging. When we compared 
the biofilm untreated control (growth control) to the biofilm 
samples treated with the highest titers of phages tested for 
24  h, we  observed that 90% of heat reduction of the curves 
in calorimetric graphs corresponds to a moderate reduction 
of S. aureus viability (≈2 log10 and ≈3.5 log10 CFU/ml) for 
Sb and PYO treatments, respectively. This is consistent with 
the fact that the detection limit of the calorimeter is ≈105 CFU/
ml (Butini et  al., 2019), therefore in order to better quantify 
the remaining bacterial cells on glass beads the colony counting 
is needed.
A B
FIGURE 12 | Impact of single phage and vancomycin doses on prevention of MRSA infection and survival rates of G. mellonella larvae. A single phage dose  
(105 PFU/ml) was injected 1 h before the larvae was infected with (A) 2.5–5 ×  106 CFU/ml (B) 2.5–5 ×  107 CFU/ml of bacteria. PC, untreated control; NC, non-
manipulated; PBS, phosphate-buffered saline.
A B
FIGURE 11 | Impact of single phage and vancomycin doses on treatment of MRSA infection and survival rates of G. mellonella larvae. A single phage dose  
(105 PFU/ml) was injected 1 h before the larvae was infected with (A) 2.5–5 ×  106 CFU/ml (B) 2.5–5 ×  107 CFU/ml of bacteria. PC, untreated control; NC,  
non-manipulated; PBS, phosphate-buffered saline.
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Bacteriophages, as all viruses, infect their host cells to 
replicate themselves and release the viral progeny, meaning 
an exponential increase of the number of virus particles over 
time (Yin and Redovich, 2018). In addition, in our previous 
work, we  showed that phages can also kill persister cells after 
their resumption to a normal growing phenotype (Tkhilaishvili 
et  al., 2018b). Therefore, we  evaluated if a longer exposure 
could eradicate all sessile bacteria. We observed that the in vitro 
killing of all S. aureus biofilm-embedded cells was possible 
when bacteria were incubated over 5 and 7  days with either 
PYO (106 PFU/ml) or Sb (107 PFU/ml), respectively. A prolonged 
exposure characterized by a rise of phage number during 
bacterial lysis might facilitate the interaction by phages with 
bacterial cells, including those localized into the deepest biofilm 
layers, which determine consequently the death of all the 
adherent cells.
In a previous work, we  also showed that Sb can degrade 
the exopolysaccharide component of the matrix. Here, the 
CLSM analysis showed that the treatment of biofilm based on 
PYO had no effect on the extracellular components of the 
matrix suggesting a different enzymatic activity between the 
phage formulation tested. However, the slower lytic activity of 
phages against biofilms can be  apparently more due to the 
physiological state of sessile community and not to diffusion 
barriers (Abedon, 2017).
As an established biofilm is difficult to be  eradicated, the 
prevention of the infection is still considered the best strategy 
to reduce the cases of infections (Chen et  al., 2013). Either 
Sb or PYO showed an in vitro ability to prevent S. aureus 
biofilm formation within 24  h at titer (104 PFU/ml) lower 
than that needed for the killing of all planktonic cells of 
the initial inoculum as shown in Figure 1. In such experiment, 
we  observed only a 2 log10 CFU reduction of bacteria treated 
with 104 PFU/ml comparing to the untreated control. This 
discrepancy might be  due to the fact that in the presence 
of the beads part of the planktonic bacteria attaches on the 
material, resulting less metabolically active. This effect reduces 
the number of the replicating free-floating bacteria and 
be  more easily lysate by phages. This effect was observed 
for both phages formulation tested independently. As reported 
by in vitro observations, the adhesion of S. aureus seems to 
occur within 3  h from bacterial inoculum (Moormeier et  al., 
2014). CFUs counting after 3 h-incubation of S. aureus treated 
with 104 PFU/ml of either Sb or PYO showed that there is 
no difference in the CFU number of attached cells from 
treated and untreated samples, suggesting that Sb and PYO 
did not interfere with bacterial adhesion process. Although 
we  cannot clearly discriminate between biofilm prevention 
and biofilm disruption, here mature biofilm disruption could 
be  excluded by the fact that the phage titer 104 PFU/ml 
(determining bacteria eradication on the beads) had only a 
poor effect in disrupting the biofilms in the “antibiofilm 
activity test” (Figure  2).
In vivo experiments, performed in a G. mellonella model 
of S. aureus systemic infection, showed that both phage 
formulations at higher titer tested improved the survival of 
larvae comparing to the untreated sample and analogously to 
the effect exhibited by vancomycin used as antibiotic control.
Previous in vivo studies of the therapeutic potential of phages 
against different bacterial pathogens have used in a G. mellonella 
infection model (Desbois and Coote, 2011; Johnston et  al., 
2016; Silva et al., 2017). However, to the best of our knowledge, 
this is the first study to test phages for their ability to rescue 
MRSA-infected G. mellonella larvae from death. In our study, 
the phage was applied at 1  h before or after MRSA infection 
in order to determine if these phage formulations had a 
prophylactic and/or treatment effect. Results suggest that the 
time of administration of phage plays an important role in 
therapy of MRSA infection in larvae. When phages were applied 
1  h before infection, the survival rates were higher than in 
the groups administered phage after 1  h infection. In addition, 
our study showed that the effectiveness of phage therapy 
increased with usage of phage cocktail compared to single 
phage and a single phage dose was enough to reduce the 
mortality of larvae infected with MRSA in vivo. The low MOI 
(0.1 and 0.01) used in this study allowed for determination 
of the efficacy of the phages while avoiding the phenomenon 
of “lysis from without.” Interestingly, a MOI 0.1 determined 
the survival of more larvae comparing to the larval survival 
with a MOI 0.01, suggesting that the ratio between phages 
and bacteria is relevant for the success of the therapy. However, 
the relevance of the G. mellonella model to predict the phage 
efficacy with higher MOIs and different timings of phage 
administration remains to be  determined.
CONCLUSION
In this study, our research strongly suggests that phage PYO 
bacteriophage and Sb phages are promising for preventing device 
colonization and killing biofilm bacteria attached on a surface. 
Novel strategies for addressing coating and release of phages 
from material should be  further investigated. In addition, both 
phage formulations increased the survival of G. mellonella larvae 
preventing or treating MRSA infection compared to untreated 
control. Future work should be  considered using the phages 
against clinical strains and efficiency of treatment for systemic 
infections must be  evaluated in more complex animal models.
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